Skip to main content
Premium Trial:

Request an Annual Quote

Axela, Thermal Gradient Ink Deal for Technology Integration

NEW YORK (GenomeWeb News) – Axela today announced a development deal to integrate Thermal Gradient's rapid PCR technology into Axela's Flow-Thru Chip automated workflow.

Initially, Thermal Gradient's technology will added to Axela's patent pending approach for capturing and quantifying targeted nucleic acids. The workflow is now optimized for formalin-fixed, paraffin-embedded tissue and is designed for use with other specimens, including other biopsy samples, blood, and isolated cells.

Axela's Flow-Thru Chip platform is meant for researchers who need technology to address the gap between multiplexed PCR and high density DNA/RNA arrays, the Toronto-based firm said.

"Our technology enables us to design inexpensive devices that perform PCR in just a few minutes," Robert Juncosa, CEO of Rochester, NY-based Thermal Gradient, said in a statement. "It is our business model to adapt our PCR and other sample preparation capabilities to a partner's application. The integration of our technology with Axela's Flow-Thru Chip rapid hybridization and detection capabilities will provide a powerful automated solution for the broad markets that benefit from higher multiplex analysis."

Financial and other terms of the deal were not disclosed.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.